滿貫集團(03390.HK)與香港國標檢驗檢測及華潤廣東醫藥訂立戰略合作協議
格隆匯11月22日丨滿貫集團(03390.HK)公吿,於2021年11月22日,公司的間接全資附屬公司滿貫(亞太)集團有限公司與香港國標檢驗檢測有限公司("國標")及華潤廣東醫藥有限公司訂立戰略合作框架協議。該協議代表訂約方就於粵港澳大灣區提供藥品研發及全面商業化生產藥品的綜合服務等多個領域的廣泛合作達成初步共識。業務合作的完成取決於訂約方訂立進一步正式合作協議,方可作實。
董事認為,框架協議擬進行的業務合作與國家發展相融合,在政府推出有利政策的情況下,利用了粵港澳大灣區發展帶來的商機。中國政府於2021年三月通過的《中華人民共和國國民經濟和社會發展第十四個五年規劃和2035年遠景目標綱要》("十四五規劃")逐步推進粵港澳大灣區的發展。為配合"十四五規劃",《粵港澳大灣區發展規劃綱要》及《粵港澳大灣區中醫藥高地建設方案(2020-2025年)》推出一系列政策,包括但不限於簡化和加快藥品評審、註冊和審批程序,以彌補香港和深圳監管體系間的差距。
董事認為,框架協議使各訂約方能夠利用該等政策,以及政府對粵港澳大灣區中醫藥產業發展的巨大支持和商業潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.